[go: up one dir, main page]

MX2019012808A - Compuesto heterociclico. - Google Patents

Compuesto heterociclico.

Info

Publication number
MX2019012808A
MX2019012808A MX2019012808A MX2019012808A MX2019012808A MX 2019012808 A MX2019012808 A MX 2019012808A MX 2019012808 A MX2019012808 A MX 2019012808A MX 2019012808 A MX2019012808 A MX 2019012808A MX 2019012808 A MX2019012808 A MX 2019012808A
Authority
MX
Mexico
Prior art keywords
heterocyclic compound
expected
salt
useful
preventing
Prior art date
Application number
MX2019012808A
Other languages
English (en)
Other versions
MX390187B (es
Inventor
Zenichi Ikeda
Koji Watanabe
Shuji Kitamura
Minoru Ikoma
Takafumi Yukawa
Sachie Morimoto
Hideki Hirose
Kenjiro Sato
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2019012808A publication Critical patent/MX2019012808A/es
Publication of MX390187B publication Critical patent/MX390187B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto o una de sus sales que tiene una actividad antagonista del receptor sensible a calcio, y se espera que sea útil como agente para prevenir o tratar la insuficiencia cardíaca, la hipertensión pulmonar o similares. Los compuestos representados por la fórmula (I) o una de sus sales tiene una actividad antagonista del receptor sensible a calcio, y se espera que sea útil como agente para prevenir o tratar la insuficiencia cardíaca, la hipertensión pulmonar o similares, en donde cada símbolo se encuentra tal y como se describe en la memoria descriptiva.
MX2019012808A 2017-04-27 2018-04-26 Compuesto heterociclico. MX390187B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017087959 2017-04-27
PCT/JP2018/016995 WO2018199235A1 (ja) 2017-04-27 2018-04-26 複素環化合物

Publications (2)

Publication Number Publication Date
MX2019012808A true MX2019012808A (es) 2022-02-21
MX390187B MX390187B (es) 2025-03-20

Family

ID=63919858

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012808A MX390187B (es) 2017-04-27 2018-04-26 Compuesto heterociclico.

Country Status (14)

Country Link
US (1) US10919891B2 (es)
EP (1) EP3617209A4 (es)
JP (1) JP7177042B2 (es)
CN (1) CN110573512B (es)
AU (1) AU2018257331B2 (es)
BR (1) BR112019022465A2 (es)
CA (1) CA3061600A1 (es)
CO (1) CO2019012270A2 (es)
IL (1) IL270155B (es)
MX (1) MX390187B (es)
RU (1) RU2768473C2 (es)
SG (1) SG11201909812VA (es)
WO (1) WO2018199235A1 (es)
ZA (1) ZA201907792B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020266566B2 (en) * 2019-05-01 2025-11-06 Boehringer Ingelheim International Gmbh Solid forms of a GlyT1 inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ528639A (en) * 2001-03-14 2005-07-29 Gruenenthal Chemie Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
AU2003265585B2 (en) 2002-08-26 2008-07-03 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
CN1771231B (zh) * 2002-08-26 2011-05-25 武田药品工业株式会社 钙受体调节性化合物及其用途
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7501405B2 (en) * 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
JP2005239611A (ja) * 2004-02-25 2005-09-08 Takeda Chem Ind Ltd ピラゾロピリミジン誘導体およびその用途
US20090304821A1 (en) 2006-03-08 2009-12-10 Takeda Pharmaceutical Company Limited Pharmaceutical Combination
RU2650111C2 (ru) * 2012-02-03 2018-04-09 Санофи Конденсированные пирролдикарбоксамиды и их применение в качестве фармацевтических средств
JP6249952B2 (ja) * 2012-10-16 2017-12-20 武田薬品工業株式会社 複素環化合物
CN104910118B (zh) 2014-03-13 2017-07-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
EP3395344B1 (en) 2015-12-25 2022-03-16 Takeda Pharmaceutical Company Limited Medicine for treating heart failure
CN118340787A (zh) 2016-03-28 2024-07-16 武田药品工业株式会社 药物

Also Published As

Publication number Publication date
MX390187B (es) 2025-03-20
EP3617209A4 (en) 2020-08-26
BR112019022465A2 (pt) 2020-05-12
US10919891B2 (en) 2021-02-16
RU2019138175A3 (es) 2021-06-10
ZA201907792B (en) 2022-03-30
IL270155B (en) 2022-07-01
CN110573512B (zh) 2022-09-06
RU2768473C2 (ru) 2022-03-24
US20200131174A1 (en) 2020-04-30
WO2018199235A1 (ja) 2018-11-01
CN110573512A (zh) 2019-12-13
AU2018257331A1 (en) 2019-11-14
RU2019138175A (ru) 2021-05-27
CO2019012270A2 (es) 2020-02-28
CA3061600A1 (en) 2019-10-25
SG11201909812VA (en) 2019-11-28
AU2018257331B2 (en) 2022-04-07
EP3617209A1 (en) 2020-03-04
IL270155A (es) 2019-12-31
JP7177042B2 (ja) 2022-11-22
JPWO2018199235A1 (ja) 2020-03-12

Similar Documents

Publication Publication Date Title
CO2020001879A2 (es) Compuesto heterocíclico y su uso
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CL2021001973A1 (es) Compuesto heterocíclico y su uso.
MX2019011783A (es) Inhibidores de ip6k.
CL2018002099A1 (es) Compuestos de piperidina sustituido y su uso
UY35821A (es) Compuesto heterocíclico
DK3684767T3 (da) Heterocykliske forbindelser som pad-inhibitorer
DOP2016000173A (es) Heteroarilos y usos de estos
EA201790112A1 (ru) Гетероциклические соединения и их применение в качестве ингибиторов орфанного рецептора гамма-t, родственного рецепторам ретиноидов (ror)
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
ECSP15028917A (es) Compuesto heterocíclico
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
DOP2016000312A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
DK3418275T3 (da) Hidtil ukendt 2,3,5-substitueret thiophenforbindelse som proteinkinasehæmmer
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
CL2017000006A1 (es) Derivados de quinolizinona como inhibidores de pi3k
ECSP17010482A (es) Novedosas pirimidinas 2,5-sustituidas
MX2020003883A (es) Composiciones que contienen derivados de acido benzoico o acido furoico y uso de los derivados para estabilidad de emulsion y de espuma.
BR112018001726A2 (pt) inibidores do vírus sincicial respiratório
BR112016028022A2 (pt) compostos de sulfonamida e seus usos como inibidores de stat5
MX2013002511A (es) Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.
CO2019012270A2 (es) Compuesto heterocíclico
MX2019012810A (es) Compuesto heterociclico.
UY37681A (es) Compuestos inhibidores de la actividad quinasa y su uso en aplicaciones terapéuticas